[A22-63] Pembrolizumab (breast cancer) - Benefit assessment according to § 35a Social Code Book V
Last updated 15.12.2022
Commission awarded on 23.06.2022 by the Federal Joint Committee (G-BA).
Adult patients with locally advanced, or early-stage triple-negative breast cancer at high risk of recurrence, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.